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Introduction {#jdi13014-sec-0005}
============

The increase of elderly patients with type 2 diabetes is a major problem all over the world, especially in Japan. Sarcopenia, an age‐related decrease in the strength of skeletal muscle accompanied with the loss of muscular mass, is known to impair physical ability[1](#jdi13014-bib-0001){ref-type="ref"}, [2](#jdi13014-bib-0002){ref-type="ref"} and increase the risk of incidental falls[3](#jdi13014-bib-0003){ref-type="ref"}. Patients with type 2 diabetes are reportedly candidates for sarcopenia[4](#jdi13014-bib-0004){ref-type="ref"}, [5](#jdi13014-bib-0005){ref-type="ref"}. These patients have low muscle mass and strength in the lower extremities despite having identical grip strength to healthy individuals, which might cause mobility limitations[6](#jdi13014-bib-0006){ref-type="ref"}. In contrast, an age‐related decline in muscle strength before the reduction of muscle mass is proposed to be "dynapenia"[7](#jdi13014-bib-0007){ref-type="ref"}, [8](#jdi13014-bib-0008){ref-type="ref"}. However, the clinical impact of dynapenia on physical activity and the risk of incidental falls in patients with type 2 diabetes has not been determined.

Advanced glycation end‐products (AGEs), produced by non‐enzymatic binding of glucose and proteins, accumulate in various tissues with aging[9](#jdi13014-bib-0009){ref-type="ref"}, [10](#jdi13014-bib-0010){ref-type="ref"}, [11](#jdi13014-bib-0011){ref-type="ref"}, [12](#jdi13014-bib-0012){ref-type="ref"}. Chronic hyperglycemia also accelerates AGEs accumulation, which causes diabetic vascular complications, such as macro‐ and micro‐angiopathy, through oxidative stress and chronic inflammation[9](#jdi13014-bib-0009){ref-type="ref"}. A longer duration of diabetes or sustained hyperglycemia is suggested to be relevant to muscle weakness in patients with diabetes[13](#jdi13014-bib-0013){ref-type="ref"}. However, the relationship among AGEs accumulation in patients with type 2 diabetes and reduced muscle mass and strength, and physical performance is unclear. In addition, the association between AGEs accumulation and dynapenia in patients with type 2 diabetes has not been determined. Therefore, the aim of the present cross‐sectional study was to investigate the clinical impact of sarcopenia and dynapenia, and clarify the influence of AGEs accumulation on muscle mass and strength in patients with type 2 diabetes.

Material and Methods {#jdi13014-sec-0006}
====================

Study design and participants {#jdi13014-sec-0007}
-----------------------------

The present study was approved by the ethics committee of Tokushima University Hospital (approval \#2281). The inclusion criteria were outpatients with type 2 diabetes aged ≥30 years at Tokushima University Hospital. Written informed consent was obtained from all participants. Patients who were taking steroids, and those with severe peripheral neuropathy, end‐stage renal failure, history of stroke, myopathy and motor functional disorders were excluded. A cross‐sectional analysis was carried out of each set of data obtained from July until December 2016.

Assessment of body composition and muscle strength {#jdi13014-sec-0008}
--------------------------------------------------

The body mass index (BMI) was determined by the formula of bodyweight (kg) divided by height squared (m^2^). Percentage body fat (%body fat) and skeletal muscle mass were measured as previously reported using the bioelectrical impedance analysis‐based measurements[14](#jdi13014-bib-0014){ref-type="ref"}, which was shown to have a strong positive correlation with dual‐energy X‐ray absorptiometry in elderly individuals[3](#jdi13014-bib-0003){ref-type="ref"}, [15](#jdi13014-bib-0015){ref-type="ref"}. Skeletal muscle mass index (SMI) was calculated by dividing the upper‐ and lower‐limb skeletal muscle mass by height squared[1](#jdi13014-bib-0001){ref-type="ref"}, [2](#jdi13014-bib-0002){ref-type="ref"}. Visceral fat area was measured with a medical visceral fat measuring device using multifrequency bioelectrical impedance analysis (HDS‐2000 DUALSCAN; OMRON, Kyoto, Japan).

Grip strength, knee extension strength and gait speed were determined to evaluate muscle strength and physical performance. Upper extremity muscle strength was measured with each hand using maximum isometric grip strength (GRIP‐D TKK5401; Takei, Niigata, Japan) in a standing position[1](#jdi13014-bib-0001){ref-type="ref"}, [2](#jdi13014-bib-0002){ref-type="ref"}, [3](#jdi13014-bib-0003){ref-type="ref"}. The highest grip strength value was used as the muscle strength in the present study. A handheld dynamometer (μTas F‐1; ANIMA, Tokyo, Japan) was utilized to evaluate maximum isometric knee extension strength, which represents lower extremity muscle strength. The participants sat on a bench and the force sensor was fixed firmly by a belt on the distal end of the tibia to a rigid bar. We defined the maximal isometric knee extension strength as the highest value of three trials[16](#jdi13014-bib-0016){ref-type="ref"}. We multiplied the maximal isometric knee extension strength and the lever arm strength to calculate knee extension torque (Nm). The knee extension torque divided by bodyweight (Nm/kg) was calculated to estimate the knee extension strength. Measured body height was used to estimate lever arm strength[17](#jdi13014-bib-0017){ref-type="ref"}, [18](#jdi13014-bib-0018){ref-type="ref"}. The total 5‐m walk time was recorded as gait speed[1](#jdi13014-bib-0001){ref-type="ref"}, [2](#jdi13014-bib-0002){ref-type="ref"}, [3](#jdi13014-bib-0003){ref-type="ref"}.

Definition of sarcopenia and dynapenia {#jdi13014-sec-0009}
--------------------------------------

We used the definition of sarcopenia proposed by the Asian Working Group for Sarcopenia[2](#jdi13014-bib-0002){ref-type="ref"}, which involves low handgrip strength, slow gait speed and low SMI. The cut‐off values of low muscle mass, strength and physical performance according to the definition of sarcopenia and dynapenia are shown in Appendix [S1](#jdi13014-sup-0001){ref-type="supplementary-material"}. Dynapenia was defined according to the proposed criteria by Clark and Manini as low handgrip strength, low knee extension strength and a normal SMI[7](#jdi13014-bib-0007){ref-type="ref"}, [8](#jdi13014-bib-0008){ref-type="ref"}, [18](#jdi13014-bib-0018){ref-type="ref"}. Patients who were not diagnosed with sarcopenia or dynapenia were defined as the control group.

Skin autofluorescence measurement {#jdi13014-sec-0010}
---------------------------------

Skin autofluorescence (AF) has been proposed as a marker of AGEs accumulation in the skin[19](#jdi13014-bib-0019){ref-type="ref"}. Skin AF was strongly correlated with the specific AGEs content in skin biopsy samples as reported previously[20](#jdi13014-bib-0020){ref-type="ref"}, [21](#jdi13014-bib-0021){ref-type="ref"}. Skin AF was measured by an AGE Reader™ (DiagnOptics Technologies BV, Groningen, the Netherlands), which estimates skin accumulation of AGEs according to the fluorescence properties of AGEs. The measurement protocol was reported in detail previously[19](#jdi13014-bib-0019){ref-type="ref"}, [20](#jdi13014-bib-0020){ref-type="ref"}, [21](#jdi13014-bib-0021){ref-type="ref"}. Skin AF was measured on the ventral side of the forearm three times in series, and the averaged value was utilized in the present study. Repeated skin AF measurements within a day showed an overall Altman error rate of 5.03%[20](#jdi13014-bib-0020){ref-type="ref"}.

Clinical laboratory data {#jdi13014-sec-0011}
------------------------

Glycated hemoglobin (HbA1c), serum high‐density lipoprotein cholesterol, serum triglyceride and serum creatinine were examined in the hospital using standard laboratory methods. The duration of diabetes, history of hypertension and dyslipidemia, and use of antidiabetic medications were collected from the medical records of each individual participant. The estimated glomerular filtration rate (eGFR) was calculated using the following equation (eGFR = 194 × serum creatinine \[mg/dL\] − 1.094 × age − 0.287 \[×0.739 for females\]), and eGFR \<60 mL/min/1.73 m^3^ was defined as chronic kidney disease according to the criteria of Japanese Society of Nephrology[22](#jdi13014-bib-0022){ref-type="ref"}. Serum pentosidine, one of AGEs in the circulation[10](#jdi13014-bib-0010){ref-type="ref"}, was measured using a competitive enzyme‐linked immunosorbent assay kit. Blood pressure was measured with patients in the supine position.

Diabetic neuropathy was diagnosed in patients who fulfilled at least two of the following criteria: complaint of bilateral sensory symptoms in the toes and soles of the feet (specifically, at least two of the following: numbness, pain and dysesthesia), a bilaterally diminished or absent Achilles tendon reflex, and a bilaterally decreased vibratory sensation in the inner malleolus[23](#jdi13014-bib-0023){ref-type="ref"}.

Assessment of physical activity and history of falls {#jdi13014-sec-0012}
----------------------------------------------------

The diagnostic survey method with a short version of the International Physical Activity Questionnaire[24](#jdi13014-bib-0024){ref-type="ref"}, [25](#jdi13014-bib-0025){ref-type="ref"} was used to estimate physical activity in each patient. The time spent within a week (7 days) on various activities which, depending on their intensity, were ascribed a specified metabolic equivalent of 1 kcal/kg/h (MET). The International Physical Activity Questionnaire questionnaires collected MET data for each participant. The short version of the International Physical Activity Questionnaire details moderate (four MET) and intensive (eight MET) physical activity, as well as walking (3.3 MET). The data collected from the questionnaires were used to calculate the weekly energy consumption (EC) expressed as kilocalories per week[25](#jdi13014-bib-0025){ref-type="ref"}. An interview was carried out about the history of falls within the past year for each participant. A history of falls was defined as one or more falls. A "fall event" was identified for each participant who suddenly lost his/her balance and collapsed[3](#jdi13014-bib-0003){ref-type="ref"}, [26](#jdi13014-bib-0026){ref-type="ref"}.

Statistical analysis {#jdi13014-sec-0013}
--------------------

SPSS Statistics 22 (IBM Japan, Tokyo, Japan) was used for the statistical processing. All data are presented as mean ± standard deviation. Intergroup comparisons (control of non‐sarcopenia and dynapenia, sarcopenia, dynapenia) were assessed using an unpaired one‐way analysis of variance (continuous variables) or χ^2^‐test (categorical variables). Uni‐ and multivariate logistic regression analyses were used to calculate the cross‐sectional association of a low SMI, low grip strength, slow gait speed, low knee extension strength, sarcopenia and dynapenia (input of covariates: age, female sex, %body fat, HbA1c, skin AF, serum pentosidine, eGFR, diabetic neuropathy and EC). Using the logistic regression models, the odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Using a stepwise procedure, covariates in the multivariate logistic regression analyses were selected. The correlation analysis between skin AF/pentosidine and other clinical parameters used Pearson\'s correlation coefficient and multiple regression analyses. Statistical significance was defined as a *P*‐value \<0.05.

Results {#jdi13014-sec-0014}
=======

Clinical characteristics of sarcopenia and dynapenia {#jdi13014-sec-0015}
----------------------------------------------------

The total of 166 Japanese participants with type 2 diabetes (99 men, 67 women) aged ≥30 years was enrolled in the present study. The prevalence of sarcopenia, dynapenia and those components are shown in Figure [1](#jdi13014-fig-0001){ref-type="fig"}. Of all participants with type 2 diabetes, 7.2% were diagnosed with sarcopenia and 13.9% with dynapenia. Patients with type 2 diabetes aged ≥65 years had a significantly higher rate of sarcopenia and dynapenia than those aged \<65 years (sarcopenia: *P* = 0.033, dynapenia: *P* \< 0.001). The prevalence of low SMI, low grip strength, slow gait speed and low knee extension strength were 11.5, 22.3, 6.6 and 59.0%, respectively. The patients aged ≥65 years had a significantly higher rate of low SMI, low grip strength and low gait speed values than those aged \<65 years (low SMI: *P* = 0.014, low grip strength: *P* \< 0.001, slow gait speed: *P* = 0.001). In contrast, there was no significant difference in the prevalence of low knee extension strength between patients aged ≥65 and \<65 years.

![Prevalence of sarcopenia, dynapenia and those components.](JDI-10-1332-g001){#jdi13014-fig-0001}

The clinical characteristics of the study patients with sarcopenia and dynapenia are shown in Table [1](#jdi13014-tbl-0001){ref-type="table"}, and Appendices [S2](#jdi13014-sup-0001){ref-type="supplementary-material"} and [S3](#jdi13014-sup-0001){ref-type="supplementary-material"}. Sarcopenic patients were older with longer duration of diabetes, and had a higher rate of incidental falls, skin AF and serum pentosidine, and lower BMI and %body fat than those of control patients. In contrast, dynapenic patients with type 2 diabetes were also older with longer duration of diabetes, and had higher percentage incidence of falls and skin AF, but had higher BMI and %body fat than those of control patients (Table [1](#jdi13014-tbl-0001){ref-type="table"}). Dynapenic patients had higher BMI, %body fat and visceral fat area, and had a lower skin AF than those of sarcopenic patients (Table [1](#jdi13014-tbl-0001){ref-type="table"}).

###### 

Clinical characteristics of the study patients with sarcopenia and dynapenia

                                 Control (*n* = 131)   Sarcopenia (*n* = 12)   *P*‐value (control vs sarcopenia)   Dynapenia (*n* = 23)   *P*‐value (control vs dynapenia)   *P*‐value (sarcopenia vs dynapenia)
  ------------------------------ --------------------- ----------------------- ----------------------------------- ---------------------- ---------------------------------- -------------------------------------
  Age (years)                    60.7 ± 11.8           70.8 ± 12.6             0.006                               73.0 ± 7.6             \<0.001                            0.523
  Female (%)                     37.4                  33.3                    1.000                               60.9                   0.041                              0.164
  Incident of fall (%)           16.0                  58.3                    0.002                               47.8                   0.001                              0.725
  BMI (kg/m^2^)                  26.6 ± 4.7            20.3 ± 2.5              \<0.001                             27.3 ± 5.2             0.550                              \<0.001
  %Body fat (%)                  30.2 ± 8.0            22.5 ± 8.0              0.002                               34.6 ± 8.6             0.016                              \<0.001
  Visceral fat area (cm^2^)      109 ± 50              52 ± 38                 0.002                               121 ± 56               0.371                              0.004
  Duration of diabetes (years)   11.0 ± 7.6            18.3 ± 11.9             0.003                               17.0 ± 10.1            0.012                              0.657
  HbA1c (%)                      7.1 ± 1.1             7.1 ± 0.9               0.812                               7.2 ± 0.8              0.943                              0.711
  Skin AF (AU)                   2.57 ± 0.52           3.34 ± 0.70             \<0.001                             2.91 ± 0.54            0.005                              0.049
  Pentosidine (μg/mL)            0.0653 ± 0.0312       0.1025 ± 0.0609         \<0.001                             0.0766 ± 0.0499        0.257                              0.326
  TG (mg/dL)                     168 ± 184             127 ± 47                0.462                               182 ± 17               0.562                              0.327
  HDL (mg/dL)                    55 ± 16               62 ± 28                 0.394                               51 ± 13                0.314                              0.103
  Dyslipidemia (%)               50.4                  16.7                    0.033                               47.8                   1.000                              0.139
  SBP (mmHg)                     139 ± 20              137 ± 13                0.687                               129 ± 30               0.051                              0.389
  DBP (mmHg)                     84 ± 15               74 ± 5                  \<0.001                             77 ± 8                 0.001                              0.348
  Hypertension (%)               55.7                  41.7                    0.38                                56.5                   1.000                              0.489
  Diabetic neuropathy (%)        55.0                  58.3                    1.000                               52.2                   0.824                              1.000
  eGFR (mL/min/1.73 m^3^)        73.7 ± 23.4           58.4 ± 19.2             0.030                               53.3 ± 20.5            \<0.001                            0.446
  EC (kcal/day)                  123 ± 186             24 ± 43                 \<0.001                             73 ± 88                0.048                              0.104

Data are shown as the mean value ± standard deviation. %Body fat, percentage of body fat; AF, autofluorescence; BMI, body mass index; DBP, diastolic blood pressure; EC, energy consumption of three or more metabolic equivalents; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.
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ORs for low muscle mass, strength and physical performance {#jdi13014-sec-0016}
----------------------------------------------------------

The ORs of clinical parameters for low muscle mass and strength, and physical performance in patients with type 2 diabetes are shown in Table [2](#jdi13014-tbl-0002){ref-type="table"}. Skin AF and serum pentosidine were inversely associated with SMI in the univariate model. After the adjustment for all covariates on stepwise regression, skin AF and serum pentosidine remained to be inversely associated with SMI (skin AF: OR 6.38, 95% CI 1.93--21.08; serum pentosidine: OR 1.02, 95% CI 1.00--1.03).

###### 

Odds ratios of lower muscle mass, strength and physical function in patients with type 2 diabetes

                        SMI \< cut‐off value   Grip strength \< cut‐off value                                                                                              
  --------------------- ---------------------- -------------------------------- --------- ------ ------------- --------- ------ ------------ --------- ------ ------------ ---------
  Age                   1.05                   1.01--1.10                       0.028     NS                             1.11   1.06--1.16   \<0.001   1.09   1.04--1.15   \<0.001
  Female                NS                                                                NS                             NS                            NS                  
  %Body fat             0.85                   0.78--0.91                       \<0.001   0.85   0.77--0.92    \<0.001   NS                            NS                  
  HbA1c                 NS                                                                NS                             NS                            NS                  
  Skin AF               7.4                    2.82--19.45                      \<0.001   6.38   1.93--21.08   0.002     4.65   2.22--9.73   \<0.001   3.55   1.57--8.00   0.02
  Pentosidine           1.02                   1.01--1.03                       \<0.001   1.02   1.00--1.03    0.013     1.01   1.00--1.02   0.009     NS                  
  eGFR                  NS                                                                NS                             0.96   0.94--0.98   \<0.001   0.97   0.95--0.99   0.023
  Diabetic neuropathy   NS                                                                NS                             NS                            NS                  
  EC                    NS                                                                NS                             NS                            NS                  

                        Gait speed \< cutoff value   Knee extension strength \< cutoff value                                                                                         
  --------------------- ---------------------------- ----------------------------------------- ------- ------ ------------ ------- ------ ------------ --------- ------ ------------ ---------
  Age                   1.15                         1.05--1.25                                0.002   1.16   1.06--1.27   0.002   NS                            NS                  
  Female                NS                                                                             NS                          2.78   1.42--5.42   0.003     NS                  
  %Body fat             NS                                                                             NS                          1.08   1.04--1.13   \<0.001   1.10   1.05--1.15   \<0.001
  HbA1c                 NS                                                                             NS                          NS                            NS                  
  Skin AF               NS                                                                             NS                          2.68   1.46--4.95   0.002     3.68   1.87--7.23   \<0.001
  Pentosidine           NS                                                                             NS                          1.01   1.00--1.02   0.039     NS                  
  eGFR                  0.96                         0.93--0.99                                0.012   NS                          NS                            NS                  
  Diabetic Neuropathy   NS                                                                             NS                          2.09   1.11--3.92   0.022     NS                  
  EC                    NS                                                                             NS                          NS                            NS                  

%Body fat, percentage of body fat; AF, autofluorescence; EC, energy consumption of three or more metabolic equivalents; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; NS, not significant.
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Skin AF and serum pentosidine were also inversely associated with grip strength and knee extension strength, respectively, in the univariate model. Skin AF remained to be inversely associated with grip strength and knee extension strength (grip strength: OR 3.55, 95% CI 1.57--8.00; knee extension strength: OR 3.68, 95% CI 1.87--7.23) after adjustment for all covariates by stepwise regression. The results of the present study showed that skin AF was an independent determinant of low SMI, low grip strength and knee extension strength.

ORs for the risk of sarcopenia and dynapenia {#jdi13014-sec-0017}
--------------------------------------------

The ORs of the risk for sarcopenia and dynapenia in type 2 diabetes patients are shown in Table [3](#jdi13014-tbl-0003){ref-type="table"}. Age, skin AF, serum pentosidine, and a decrease in eGFR and %body fat were significantly associated with the prevalence of sarcopenia in a univariate model (Table [3](#jdi13014-tbl-0003){ref-type="table"}). The association between skin AF and the prevalence of sarcopenia remained significant (skin AF: OR 7.73, 95% CI 2.13--28.02) after the adjustment for all covariates by stepwise regression.

###### 

Odds ratios of sarcopenia and dynapenia complications in type 2 diabetes patients

                        Sarcopenia   Dynapenia                                                                                              
  --------------------- ------------ ------------- --------- ------ ------------- ------- ------ ------------ --------- ------ ------------ ---------
  Age                   1.09         1.02--1.17    0.01      NS                           1.13   1.07--1.21   \<0.001   1.14   1.07--1.21   \<0.001
  Female                NS                                   NS                           2.6    1.05--6.46   0.039     NS                  
  %Body fat             0.89         0.82--0.96    0.003     0.91   0.83--0.99    0.045   1.07   1.01--1.14   0.018     1.11   1.03--1.19   0.004
  HbA1c                 NS                                   NS                           NS                            NS                  
  Skin AF               10.08        3.08--32.95   \<0.001   7.73   2.13--28.02   0.002   3.41   1.42--8.21   0.006     3.03   1.07--8.54   0.036
  Pentosidine           1.02         1.01--1.04    0.002     1.02   1.00--1.03    0.017   NS                            NS                  
  eGFR                  0.97         0.94--0.99    0.031     NS                           NS                            NS                  
  Diabetic Neuropathy   NS                                   NS                           NS                            NS                  
  EC                    NS                                   NS                           NS                            NS                  

%Body fat, percentage of body fat; AF, autofluorescence; EC, energy consumption of three or more metabolic equivalents; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; NS, not significant.
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Age, %body fat and skin AF were significantly associated with the prevalence of dynapenia in a univariate analysis. Percentage body fat and skin AF are significantly associated with the prevalence of dynapenia (%body fat: OR 1.11, 95% CI 1.03--1.19; skin AF: OR 3.03, 95% CI 1.07--8.54) after the adjustment for all covariates by stepwise regression. Elevation of skin AF was the independent risk factor for both sarcopenia and dynapenia.

In contrast, the use of antidiabetic agents was not significantly associated with sarcopenia nor dynapenia on the univariate and multivariate analyses (Appendix [S3](#jdi13014-sup-0001){ref-type="supplementary-material"}).

Correlation analysis between skin AF/pentosidine and other clinical parameters {#jdi13014-sec-0018}
------------------------------------------------------------------------------

The correlation analysis between skin AF/pentosidine and other clinical parameters is shown in Appendix [S4](#jdi13014-sup-0001){ref-type="supplementary-material"}. Skin AF was significantly correlated with circulating serum pentosidine, and these markers of AGEs were correlated with age, duration of diabetes and decrease in eGFR. In addition, skin AF was inversely correlated with BMI and EC. Multiple regression analyses showed that the age, duration of diabetes and EC were independent determinants of skin AF (age: β = 0.189, *P* = 0.025, duration of diabetes: β = 0.165, *P* = 0.049, EC: β = −0.208, *P* = 0.010), and the duration of diabetes and eGFR were significantly associated with serum pentosidine level (duration of diabetes: β = 0.195, *P* = 0.018, eGFR: β = −0.279, *P* = 0.001).

Discussion {#jdi13014-sec-0019}
==========

Here, we showed for the first time that dynapenia is observed approximately twofold more frequently than sarcopenia, and these complications are associated with a comparable incidence of incidental falls in patients with type 2 diabetes. The typical clinical characteristics of dynapenia are high %body fat, as well as aging. In addition, accumulated AGEs were significantly associated with low muscle strength, as well as low muscle mass, and related to the prevalence of sarcopenia and dynapenia in patients with type 2 diabetes.

The previous studies showed that the prevalence of sarcopenia was 4.1--11.5% in the general elderly population[27](#jdi13014-bib-0027){ref-type="ref"} and 14.8% in type 2 diabetes[28](#jdi13014-bib-0028){ref-type="ref"} according to the Asian Working Group for Sarcopenia criteria. In contrast, the prevalence rate of dynapenia, defined by low handgrip strength and normal SMI, was 35.0% in men (mean age 83.8 ± 6.8 years) and 27.1% in women (mean age 82.5 ± 6.4 years) of general elderly Japanese aged ≥65 years, and those were twofold higher than those of sarcopenia (men 25.0%, women 22.7%)[29](#jdi13014-bib-0029){ref-type="ref"}. In the present study, we confirmed an equivalent prevalence rate of sarcopenia in patients with type 2 diabetes, and that the prevalence rate of dynapenia was also approximately twofold higher than that of sarcopenia. However, the average age of patients with type 2 diabetes in the present study (73.9 ± 6.6 years) was approximately 10 years younger than the previous reports[29](#jdi13014-bib-0029){ref-type="ref"}. In addition, 38.8 and 62.4% of patients with type 2 diabetes aged ≥65 years showed low handgrip and knee extension strength in the present study, respectively, and this prevalence was higher than that of the Japanese general elderly population[30](#jdi13014-bib-0030){ref-type="ref"}. It is possible that type 2 diabetes might complicate muscle weakness at a younger age than the general population. Therefore, the typical characteristics of muscle dysfunction in elderly patients with type 2 diabetes could be lower muscle strength in the extremities, but not a decrease in muscle volume compared with individuals without type 2 diabetes. Furthermore, impaired knee extension strength was observed frequently, even at the age of \<65 years (Figure [1](#jdi13014-fig-0001){ref-type="fig"}), suggesting that the muscle strength of lower limbs could be a better indicator of muscle dysfunction than the grip strength in patients with type 2 diabetes.

Sarcopenia is known to be a risk factor for incidental falls in general elderly people[31](#jdi13014-bib-0031){ref-type="ref"}. In the present study, the complication of dynapenia increased the incidence of falls, as well as sarcopenia (47.8% vs 58.3%) in patients with type 2 diabetes. Therefore, we should be aware of dynapenia, as well as sarcopenia, to prevent incidental falls and fractures among elderly patients with type 2 diabetes.

Sarcopenia and dynapenia were observed in elderly patients with longer duration of diabetes, and the difference of clinical characteristics between these comorbidities was adiposity, such as BMI, %body fat and visceral fat area. Sarcopenic patients showed low BMI, whereas dynapenic patients showed comparable BMI with patients without sarcopenia and dynapenia. A previous study reported that obese patients with type 2 diabetes had lower muscle strength than healthy normal bodyweight participants[5](#jdi13014-bib-0005){ref-type="ref"}, [6](#jdi13014-bib-0006){ref-type="ref"}. The accumulation of intramuscular fat is inversely associated with lower limb muscle function in elderly individuals[32](#jdi13014-bib-0032){ref-type="ref"}. In contrast, increased bodyweight could be an overload to maintain muscle volume. Indeed, high %body fat was significantly and independently associated with the risk of dynapenia in patients with type 2 diabetes in the present study. Elderly obese patients with type 2 diabetes, therefore, might have a higher prevalence of dynapenia, but not sarcopenia. However, because the intramuscular fat, body fat mass by site and adipokine levels were not evaluated, the detailed mechanism for developing dynapenia could not be clarified in the present study.

AGEs, which are produced through non‐enzymatic glycation, are accumulated in various tissues under the diabetic condition; that is, chronic hyperglycemia[9](#jdi13014-bib-0009){ref-type="ref"}, [10](#jdi13014-bib-0010){ref-type="ref"}, [11](#jdi13014-bib-0011){ref-type="ref"}, [12](#jdi13014-bib-0012){ref-type="ref"}. Skin AF, representing the accumulation of AGEs, was inversely associated with SMI, grip strength and knee extension strength in an adjusted multivariate logistic regression model in the present study. As reported previously, reduced muscle mass, regarded as the primary phenotype of sarcopenia, is associated with accumulated AGEs in humans as they age[33](#jdi13014-bib-0033){ref-type="ref"}. Oxidative stress and inflammatory cytokines are increased by AGEs[34](#jdi13014-bib-0034){ref-type="ref"}. In addition, AGEs induce cross‐link and breakdown of muscular protein in elderly humans and a rodent aging model[35](#jdi13014-bib-0035){ref-type="ref"}. The expression of AGEs receptors in muscle tissue is increased with aging[36](#jdi13014-bib-0036){ref-type="ref"}, [37](#jdi13014-bib-0037){ref-type="ref"}, suggesting that the intracellular signaling of AGEs--AGEs receptors is accelerated in the muscle of elderly patients with diabetes. AGEs levels in the circulation and in the various tissues are increased under the diabetic condition[9](#jdi13014-bib-0009){ref-type="ref"}, [10](#jdi13014-bib-0010){ref-type="ref"}, [11](#jdi13014-bib-0011){ref-type="ref"}, [12](#jdi13014-bib-0012){ref-type="ref"}. AGEs accumulation in the hind limb muscles of diabetic mice is associated with the decline in muscle mass, muscle endurance and regenerative capacity[38](#jdi13014-bib-0038){ref-type="ref"}. Furthermore, it was reported in a human study that AGEs accumulation in the fast twitch muscle fibers cross‐links with muscle collagen, increases muscle stiffness and reduces the tonic force of the muscle contraction[14](#jdi13014-bib-0014){ref-type="ref"}, [39](#jdi13014-bib-0039){ref-type="ref"}, [40](#jdi13014-bib-0040){ref-type="ref"}. Thus, it is suggested that accumulated AGEs levels are associated with muscle mass reduction and sarcopenia in patients with type 2 diabetes.

HbA1c was not associated with low muscle mass, grip strength and knee extension strength in the present study. We recently showed that lower limb muscle strength was inversely associated with skin AF, but not associated with HbA1c in patients with type 1 diabetes[14](#jdi13014-bib-0014){ref-type="ref"}. It was also reported recently that skin AF reflects integration over the past 15 years' long‐term glycemic control, but not present glycemic control in patients with type 1 diabetes[41](#jdi13014-bib-0041){ref-type="ref"}. These results suggest that muscle weakness reflects long‐term glycemic control in both patients with type 1 and type 2 diabetes. The serum pentosidine was not inversely associated with muscle strength on an adjusted multivariate logistic regression model (including covariate of skin AF) in the present study. The duration of type 2 diabetes was positively correlated with skin AF and serum pentosidine, but not HbA1c significantly (Appendix [S4](#jdi13014-sup-0001){ref-type="supplementary-material"}). Also, serum pentosidine was positively correlated with skin AF. Serum pentosidine was inversely associated with eGFR. Taken together, it is suggested that chronic hyperglycemia, aging and a long duration of disease increase the accumulation of AGEs, which could contribute to impaired muscle strength in patients with type 2 diabetes according to the present study. Improvements of glycemic control could attenuate the accumulation of AGEs. Skin AF was inversely associated with EC. Physical inactivity is a related factor for obesity and type 2 diabetes, both of which can accelerate the formation and accumulation of AGEs. In the present study, patients with type 2 diabetes were associated with a high prevalence of sarcopenia and dynapenia, even for those aged \<65 years. Therefore, the early diagnosis of muscle weakness is important, and good glycemic control and weight management with exercise and dietary intervention might be beneficial to prevent the progression of muscle weakness in these patients.

Several studies have showed that the use of statins is associated with muscle weakness[42](#jdi13014-bib-0042){ref-type="ref"}, but such a finding was not consistent in the other studies, including the present study. In addition, the participants in the present study had type 2 diabetes, which could be a strong inducer of muscle weakness. Therefore, we could not find any relationship between the use of statins and the prevalence of sarcopenia or dynapenia in the present study.

The present study had several limitations. First, it is impossible to infer causality because of the cross‐sectional design, although we showed a significant association between AGEs accumulation and sarcopenia and dynapenia in patients with type 2 diabetes. Second, there was no information about what the participants ate, which could affect both muscle mass and strength. Insufficient protein intake might result in the progression of sarcopenia or decline in muscle mass[1](#jdi13014-bib-0001){ref-type="ref"}, [2](#jdi13014-bib-0002){ref-type="ref"}. Third, we could not evaluate biomarkers of inflammation (such as tumor necrosis factor‐α, interleukin‐6), growth factors (such as insulin‐like growth factor) or adipokines (such as leptin, adiponectin)[43](#jdi13014-bib-0043){ref-type="ref"}. Finally, the small sample size of participants from a single hospital in Japan was a major limitation to generalizing this result. Therefore, further study is necessary to clarify the prevalence rate of dynapenia, and the relationship between AGEs and muscle weakness in a multi‐institutional cohort study.

In conclusion, the prevalence rate of dynapenia was higher than sarcopenia. Dynapenia tended to be observed in obese patients with type 2 diabetes. Finally, accumulated AGEs was an independent factor for sarcopenia and dynapenia in patients with type 2 diabetes.
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